Abstract

Chronic infected wounds present significant challenges globally, as persistent bacterial colonization would lead to prolonged inflammation, impaired tissue repair, etc. This study describes a novel MMP-responsive GelMA hydrogel dispersed with AgNPs and Res co-loaded cationic silicasomes for chronic infected wound treatment. The resulting silicasomes-GelMA hydrogel could firmly adhere to the wound surface, rapidly absorb the blood and exudate from the wound. GelMA was gradually degraded by the over-expressed MMP9 enzymes in the wound environment. The released silicasomes could effectively eradicate MRSA by targeting bacterial cell walls and membranes, with intracellular bacterial clearance rate of 83.75%-88.14%, which promoted the angiogenesis and re-epithelialization process, reduced inflammatory response, and achieved nine times higher neovasculation and half shortened skin barrier regeneration period. Collectively, our designed silicasomes-GelMA hydrogel could achieve hemostasis, anti-inflammation, antibacterial, and tissue regeneration effects simultaneously by a single dose, and is a promising drug delivery platform for chronic infected wound therapy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.